Sagimet Biosciences Inc Stock Ownership - Who owns Sagimet Biosciences?

Insider buying vs selling

Have Sagimet Biosciences Inc insiders been buying or selling?
David HappelPresident CEO2024-03-2612,100$5.27
David HappelPresident CEO2023-12-071,600$4.10
David HappelPresident CEO2023-11-16590$2.35
George KembleExecutive Chairman2023-09-075,630$0.79
Beth C. SeidenbergDirector2023-07-1846,875$16.00
New Enterprise Associates 13 LP10% Owner2023-07-1830,000$16.00
New Enterprise Associates 13 LP10% Owner2023-07-18662$16.00
New Enterprise Associates 13 LP10% Owner2023-07-1813,404$0.80

1 of 1

SGMT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SGMT insiders and whales buy or sell their stock.

SGMT Shareholders

What type of owners hold Sagimet Biosciences Inc stock?
Patrick J. Kerins9.44%3,013,414$13.92MInsider
Forest Baskett9.44%3,011,575$13.91MInsider
Scott D. Sandell9.42%3,007,272$13.89MInsider
Nea Partners 13 Limited Partnership9.40%3,000,275$13.86MInsider
New Enterprise Associates 13 LP9.40%3,000,275$13.86MInsider
Point72 Asset Management LP8.36%2,666,784$12.32MInstitution
Beth C. Seidenberg6.36%2,031,118$9.38MInsider
Blackrock Inc6.35%2,025,611$9.36MInstitution
Nea Management Company LLC6.27%2,000,275$9.24MInstitution
Kpcb Pbd Associates LLC5.95%1,899,475$8.78MInsider

1 of 3

SGMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SGMT51.04%48.96%Net BuyingNet Buying
RPTX60.47%39.53%Net BuyingNet Selling
BCAB51.62%33.67%Net BuyingNet Selling
CTMX56.85%26.85%Net BuyingNet Buying
TVGN4.11%95.89%Net Selling

Sagimet Biosciences Stock Ownership FAQ

Who owns Sagimet Biosciences?

Sagimet Biosciences (NASDAQ: SGMT) is owned by 70.84% institutional shareholders, 67.96% Sagimet Biosciences insiders, and 0.00% retail investors. Patrick J. Kerins is the largest individual Sagimet Biosciences shareholder, owning 3.01M shares representing 9.44% of the company. Patrick J. Kerins's Sagimet Biosciences shares are currently valued at $14.31M.

If you're new to stock investing, here's how to buy Sagimet Biosciences stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.